Jessica J Lin Selected Research

Cell-Free Nucleic Acids

1/2019

Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jessica J Lin Research Topics

Disease

27	Neoplasms (Cancer) 01/2024 - 06/2015
22	Lung Neoplasms (Lung Cancer) 08/2023 - 01/2016
18	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2024 - 04/2016
8	Neoplasm Metastasis (Metastasis) 04/2023 - 04/2016
5	Brain Neoplasms (Brain Tumor) 01/2023 - 01/2017
3	Disease Progression 01/2022 - 01/2020
2	Thyroid Neoplasms (Thyroid Cancer) 11/2023 - 04/2022
2	Edema (Dropsy) 08/2023 - 07/2022
1	Central Nervous System Diseases (CNS Diseases) 03/2024
1	Paresthesia (Dysesthesia) 01/2024
1	Dizziness (Lightheadedness) 01/2024
1	Dysgeusia (Parageusia) 01/2024
1	Genomic Instability 08/2023
1	Mental Disorders (Mental Disorder) 01/2023
1	Chylothorax 01/2022
1	Chylous Ascites 01/2022
1	Colorectal Neoplasms (Colorectal Cancer) 01/2021
1	COVID-19 01/2021
1	Pneumonia (Pneumonitis) 01/2021
1	Urinary Bladder Neoplasms (Bladder Cancer) 10/2020
1	Melanoma (Melanoma, Malignant) 10/2020
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2020
1	medullary Thyroid cancer 01/2020
1	Adenocarcinoma of Lung 04/2016
1	Breast Neoplasms (Breast Cancer) 06/2015

Drug/Important Bio-Agent (IBA)

11	Tyrosine Kinase InhibitorsIBA 01/2024 - 04/2016
11	lorlatinibIBA 11/2023 - 01/2018
8	CrizotinibIBA 08/2023 - 01/2017
6	Anaplastic Lymphoma KinaseIBA 01/2023 - 01/2017
5	alectinibIBA 08/2023 - 11/2016
4	entrectinibIBA 05/2022 - 01/2021
4	Immune Checkpoint InhibitorsIBA 11/2021 - 01/2018
3	osimertinibIBA 01/2024 - 01/2019
3	capmatinibIBA 11/2023 - 01/2021
3	pralsetinibIBA 11/2023 - 01/2021
3	selpercatinibIBA 01/2022 - 01/2020
3	Phosphotransferases (Kinase)IBA 01/2022 - 01/2022
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2021 - 10/2018
3	Circulating Tumor DNAIBA 01/2020 - 01/2018
2	repotrectinibIBA 01/2024 - 10/2018
2	Proteins (Proteins, Gene)FDA Link 11/2023 - 01/2021
2	B7-H1 AntigenIBA 09/2022 - 07/2021
2	larotrectinibIBA 04/2022 - 01/2022
2	TropomyosinIBA 01/2022 - 01/2022
2	cabozantinibIBA 01/2021 - 10/2018
2	ErbB Receptors (EGF Receptor)IBA 01/2020 - 04/2016
2	SolventsIBA 01/2020 - 10/2018
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2019 - 01/2017
1	thiamine triphosphorate (TTP)IBA 03/2024
1	durvalumabIBA 01/2024
1	Cytidine DeaminaseIBA 08/2023
1	Hypnotics and Sedatives (Sedatives)IBA 01/2023
1	Anticonvulsants (Antiepileptic Drugs)IBA 01/2023
1	BenzodiazepinesIBA 01/2023
1	Triglycerides (Triacylglycerol)IBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	pembrolizumabIBA 11/2021
1	LigandsIBA 11/2021
1	Oxygen (Dioxygen)IBA 01/2021
1	sotorasibIBA 01/2021
1	adagrasibIBA 01/2021
1	VaccinesIBA 10/2020
1	Cell-Free Nucleic AcidsIBA 01/2019
1	vandetanib (ZD6474)IBA 10/2018
1	Sunitinib (Sutent)FDA Link 10/2018
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 04/2016
1	Gefitinib (Iressa)FDA Link 04/2016
1	Phenobarbital (Luminal)FDA Link 06/2015

Therapy/Procedure

20	Therapeutics 11/2023 - 01/2016
3	Drug Therapy (Chemotherapy) 11/2021 - 04/2016
2	Drug Tapering 08/2023 - 07/2022
2	Immunotherapy 01/2018 - 01/2017
1	Aftercare (After-Treatment) 01/2020
1	Radiotherapy 01/2018